Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CLEC10A-Targeted M2 Macrophage Repolarization With EF-M2 (Immutalon) in Patients With Moderate-to-Severe Rheumatoid Arthritis: An Open-Label, Multicenter, First-in-Human Phase I/IIa Multiple Ascending Dose Study

NCT07349420 is registered in ClinicalTrials.gov with S.LAB (SOLOWAYS) as lead sponsor.

NCT NCT07349420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07349420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CLEC10A-Targeted M2 Macrophage Repolarization With EF-M2 (Immutalon) in Patients With Moderate-to-Severe Rheumatoid Arthritis: An Open-Label, Multicenter, First-in-Human Phase I/IIa Multiple Ascending Dose Study
Lead sponsor
S.LAB (SOLOWAYS)
Phase
Phase 1/2
Overall status
Completed
Start date
June 3, 2025
Completion date
December 6, 2025
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis